原料药及中间体
- 分类：产品
- 发布时间：2021-06-07 17:47:33
- 访问量：0
概要:
详情
| No. | Generic Name | Item/Code | CAS No. | Molecular structure | 治疗领域（用途） | 状态 |
| 1 | Atorvastatin Calcium 阿托伐他汀钙 |
ATS-8 | 125971-94-0 |  |
降血脂 | USA - US-FDA GMP approved - L1: USDMF No. 18835 - API: USDMF No. 26022 EU - CEP 2012-139/CEP 2022-466 Japan - MF: 227MF10255 Canada - L1: CA-DMF(2006-162) - L4: CA-DMF(2009-192) Korea -KDMF:20130618-132-H-238-23 China - API: 1, 国药准字H20103023 -CDE Registration No.:Y20190007449 登记状态：A |
| M1 | 42558-54-3 |  |
||||
| L1 | 125971-95-1 |  |
||||
| API | 344423-98-9 |  |
||||
| 2 | Rosuvastatin Calcium 瑞舒伐他汀钙 |
R1 | 289042-12-2 |  |
降血脂 | USA - USDMF No. 25781 - US-FDA GMP approved EU -CEP 2020-243 Japan - MF: 227MF10120 China -CDE Registration No.:Y20210000578 登记状态：A |
| R1.5 | 355806-00-7 |  |
||||
| RJS3 | 147118-40-9 |  |
||||
| API | 147098-20-2 |  |
||||
| 3 | Fluvastatin sodium 氟伐他汀钠 |
API | 93957-55-2 |  |
降血脂 | China -CDE Registration No.:Y20230001392 登记状态：I |
| 4 | Clopidogrel Hydrogen Sulfate 硫酸氢氯吡格雷 |
API | 135046-48-9 120202-66-6 |
 |
抗血栓 | China -CDE Registration No.:Y20190001006 2 登记状态：A USA - USDMF No. 35081 Canada CA-DMF(2020-150) EU - CEP 2020-408 |
| SM1 | 141109-14-0 |  |
||||
| SM2 | 40412-06-4 |  |
||||
| 5 | Macitentan 马昔腾坦 |
API | 441798-33-0 |  |
肺动脉高压 | USA -USDMF No. 031658 China -CDE Registration No.:Y20190000010 登记状态：A |
| 6 | Betahistine Dihydrochloride 盐酸倍他司汀 |
API | 5579-84-0 |  |
美尼尔综合征 | China -CDE Registration No.:Y20200001060 登记状态：A |
| 7 | Selexipag 司来帕格 |
API | 475086-01-2 |  |
肺动脉高压 | China -CDE Registration No.:Y20230000520 登记状态：I |
| 8 | Ticagrelor 替格瑞洛 |
API | 274693-27-5 |  |
抗血栓 | China -CDE Registration No.:Y20190000753 登记状态：A |
| 9 | Rivaroxaban 利伐沙班 |
API | 366789-02-8 |  |
抗血栓 | China -CDE Registration No.:Y20210000022 登记状态：A EU -CEP 2021-142 |
| 10 | Doxazosin Mesylate 甲磺酸多沙唑嗪 |
Base | 74191-85-8 |  |
高血压 | China API: 国药准字H20050006 -CDE Registration No.:Y20190007511 登记状态：A Japan - MF: 218MF10823 |
| API | 77883-43-3 |  |
||||
| 11 | Idelalisib 艾代拉里斯 |
API | 870281-82-6 |  |
抗肿瘤 | USA -USDMF No.32519 |
| 12 | Palbociclib 帕布昔利布 |
POB10 | 1013916-37-4 |  |
抗肿瘤 | PV Done |
| POB15 | 1016636-76-2 |  |
PV Done | |||
| POB02 | 571188-59-5 |  |
PV Done | |||
| API | 571190-30-2 |  |
Lab Stage | |||
| 13 | Pazopanib HCL 盐酸帕唑帕尼 |
PAZ20 | 635702-60-2 |  |
抗肿瘤 | Lab Stage |
| PAZ70 | 6973-09-7 |  |
PV Done | |||
| API | 63570264-6 |  |
USA -USDMF No.034146 |
|||
| 14 | Ponatinib HCL 盐酸泊那替尼 |
API | 1114544-31-8 |  HCL |
抗肿瘤 | USA -USDMF No.035413 Canada HC MF # 2023-106 |
| 15 | Norfloxacin 诺氟沙星 |
Free Base | 70458-96-7 |  |
抗感染 | EU - CEP 2006-037 EUGMP:18MPP049HPT01 China - API: 国药准字H33021898 -CDE Registration No.:Y20190007457 登记状态：A Japan - MF: 226MF10208 Canada CA-DMF(2018-192) |
| Nicotinate Salt | 118803-81-9 |  |
||||
| 16 | Vortioxetine HBr 氢溴酸伏硫西汀 |
API | 960203-27-4 |  |
抗抑郁 | China -CDE Registration No.:Y20230001182 登记状态：I USA -USDMF No. 038847 |
| 17 | Brivaracetam 布立西坦 |
API | 357336-20-0 |
 |
抗癫痫 | China -CDE Registration No.:Y20220000078 登记状态：I |
| BVA07 | 2459389-35-4 |  |
||||
| 18 | Azelastine Hydrochloride 盐酸氮卓斯汀 |
API | 79307-93-0 |  |
抗过敏 | USA -USDMF No. 036748 |
| 19 | Sitagliptin Phosphate 磷酸西格列汀 |
API | 654671-77-9 |  |
糖尿病 | China -CDE Registration No.:Y20200001086 登记状态：A |
| 20 | Tofacitinib Citrate 枸橼酸托法替布 |
TOF30 | 1062580-52-2 |  |
类风关 | PV Done |
| API | 540737-29-9 |  |
China -CDE Registration No.:Y20210000971 登记状态：A |
|||
| 21 | Elagolix Sodium 艾拉戈克钠 |
API | 832720-36-2 |  |
子宫内膜异位症 | China -CDE Registration No.:Y20230000795 登记状态：I |
| 22 | SNAC | Carsalam卡沙兰 |
2037-95-8 |  |
合成SNAC | PV Done |
| Sodium 8-(2-hydroxybenzamido)octanoate（SNAC） | 203787-91-1 |  |
辅料 | PV Done | ||
| 23 | Methyl 3-oxovalerate 3-氧代戊酸甲酯 |
INT | 30414-53-0 |  |
Commercial |
免责声明：受有效专利保护的产品不能销往构成侵犯专利的国家。上述专利保护产品仅供研发使用，并由买方承担全部责任。
搜索